{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Borrelia burgdorferi",
        "LIAISON\u00ae Borrelia burgdorferi Serum Controls"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K062473",
    "Predicate Device Reference 510(k) Number(s)": [
        "K003754"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "February 2, 2007",
    "Summary Letter Received Date": "February 5, 2007",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi",
        "IgM antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect chemiluminescence immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Serum Control",
        "Quality control material",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Borrelia burgdorferi assay and serum controls for qualitative detection of IgG and IgM antibodies to Borrelia burgdorferi in human serum using CLIA on the LIAISON Analyzer",
    "Indications for Use Summary": "Qualitative presumptive detection of IgG and IgM antibodies to VlsE antigen of Borrelia burgdorferi in human serum for patients with signs and symptoms consistent with Lyme disease; positive or equivocal results require supplemental Western blot testing to support diagnosis",
    "fda_folder": "Microbiology"
}